Clinical trials: Human Immunodeficiency Virus Type 1
Immune Deficiency, HIV-related Gut Disease - Cause Unknown
Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment
Immune Activation persists in HIV-1 infected patients despite efficient antiretroviral treatment. This immune activation is responsible for immune deficiency as well as for non-AIDS related comorbidities, such as non-alcoholic…
- Conditions
- Immune Deficiency, HIV-related Gut Disease - Cause Unknown, Activation of Latent Virus, Other Diagnoses, Comorbidities, and Complications
- Trial name
- ACTIVIH (NCT02334943)
- Testing
- Blood test
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
HIV-Infections
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
This trial is designed to assess the swallowability of uncoated and film-coated 200 mg etravirine tablets in HIV-1 infected patients.
- Trial name
- NCT01090648
- Testing
- etravirine
- Volunteers
- 49 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
D²EFT Graphical Informed Consent
D²EFT-GIC is a substudy of D²EFT study (NCT03017872), a randomised clinical trial of second-line antiretroviral therapies. The goal of D²EFT-GIC is to evaluate a novel tool, the "Graphical Informed Consent" (GIC), within D²EFT.
- Trial name
- D²EFT-GIC (NCT04668443)
- Testing
- Graphical Informed Consent (GIC)
- Where
- Nigeria
- Volunteers
- 12 people
- Sponsor
- Kirby Institute
HIV
Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection
Combination antiretroviral treatment (cART) effectively suppresses virus replication and partially restores immune functions. However, cART cannot cure HIV infection.
- Trial name
- TEACH (NCT02443935)
- Testing
- MGN1703
- Where
- 2 sites in Denmark
- Volunteers
- 12 people
- Sponsor
- University of Aarhus
HIV Infections
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
- Trial name
- NCT03760458
- Testing
- Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
- Where
- 14 sites in United States, Botswana and 2 more
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and…
- Trial name
- NCT01701895
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Prema Menezes, PhD, PA-C
Kaposi Sarcoma, HIV-1-infection
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human…
- Conditions
- Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma
- Trial name
- NCT05411237
- Testing
- Pegylated liposomal doxorubicin, Paclitaxel
- Volunteers
- 130 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infections
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma.
- Trial name
- NCT00002177
- Testing
- Hydroxyurea, Nelfinavir mesylate, Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV-1-infection, Tuberculosis
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
This is a pharmacokinetic study investigating the effect of rifampicin on the pharmacokinetics of intracellular tenofovir-diphosphate and plasma tenofovir when coadministered with tenofovir alafenamide fumarate during the…
- Trial name
- EpiTAF (NCT04424264)
- Testing
- Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
- Where
- 2 sites in South Africa
- Volunteers
- 18 people
- Sponsor
- Professor Francois Venter
HIV Infections
Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies
To prevent mother-to-child transmission (MTCT) of HIV in resource-limited countries, a simple yet effective treatment plan is needed.
- Trial name
- NCT00120471
- Testing
- Tenofovir disoproxil fumarate
- Where
- 5 sites in Brazil, Malawi
- Volunteers
- 122 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART).
- Trial name
- NCT00006209
- Testing
- Tucaresol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Aaron Diamond AIDS Research Center
HIV-1-infection
LRAs United as a Novel Anti-HIV Strategy.
A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in…
- Trial name
- LUNA (NCT03525730)
- Testing
- Valproic Acid, Pyrimethamine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Erasmus Medical Center
Infection, Human Immunodeficiency Virus
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study.
- Trial name
- NCT02105987
- Testing
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Where
- 103 sites in United States, Canada and 1 more
- Volunteers
- 555 people
- Sponsor
- ViiV Healthcare
HIV Infections, Pregnancy
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
To evaluate the safety of rgp120/HIV-1MN vaccine in HIV-1 infected pregnant women with CD4 counts >= 400 cells/mm3. To evaluate the immunogenicity of this vaccine in pregnant women and the passive acquisition of vaccine-specific…
- Trial name
- NCT00001041
- Testing
- rgp120/HIV-1MN
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both…
- Trial name
- INSIGHT (NCT01513941)
- Testing
- Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a
- Where
- 31 sites in Australia, Brazil and 6 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
HIV-infection/Aids
Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection
Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving…
- Trial name
- NCT04297488
- Testing
- Bifidobacteria and Lactobacilli triple viable capsules
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
Primary: To determine in healthy volunteers whether priming with a vaccinia HIV-1 gp160 envelope gene recombinant vaccine (HIVAC-1e) followed by boosting with one of two subunit recombinant HIV-1 envelope vaccines (Env 2-3 and…
- Trial name
- NCT00000746
- Testing
- rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (Tenofovir…
- Trial name
- NCT02831673
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 719 people
- Sponsor
- ViiV Healthcare
HIV Infections
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer Fuzeon, compared with the standard needle/syringe supplied with commercial Fuzeon.
- Trial name
- NCT00233883
- Testing
- enfuvirtide [Fuzeon]
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
HIV -1 Infection
Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure
The persistence of a reservoir of long-lived, latently infected cells carrying replication-competent proviral DNA constitutes the main barrier to Human Immunodeficiency Virus type 1 (HIV-1) cure.
- Trial name
- GARP-PD1-HIV (NCT07692932)
- Testing
- blood drawn
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.